A multi-center study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin and micafungin using the Sensititre® YeastOne colorimetric method

Os dejo el resumen de nuestro trabajo científico colaborativo que ha sido publicado en la revista  Antimicrobial Agents and Chemotherapy y que propone para el método comercial Sensititre YeastOne puntos de corte epidemiológicos in vitro para algunos de los fármacos antifúngicos más usados en el tratamiento de las candidiasis invasoras, como son las equinocandinas anidulafungina, caspofungina y micafungina.

Felicito a mis colegas Espinel-Ingroff A, Alvarez-Fernandez M, Cantón E, Carver PL, Chen SC, Eschenauer G, Getsinger DL, Gonzalez GM, Govender NP, Grancini A, Hanson KE, Kidd SE, Klinker K, Kubin CJ, Kus JV, Lockhart SR, Meletiadis J, Morris AJ, Pelaez T, Rodriguez-Iglesias M, Sánchez-Reus F, Shoham S, Wengenack NL, Borrell Solé N, Echeverria J, Esperalba J, Gómez-G de la Pedrosa E, García García I, Linares MJ, Marco F, Merino P, Pemán J, Pérez Del Molino L, Roselló Mayans E, Rubio Calvo C, Ruiz Pérez de Pipaon M, Yagüe G, Garcia-Effron G, Guinea J, Perlin DS, Sanguinetti M, Shields R, y Turnidge J, por su excelente trabajo.

El trabajo completo sin maquetar está en AAC. ¡Si encontráis a Wally hay premio!

Este es su Resumen:

Neither breakpoints (BPs) nor epidemiological cutoff values (ECVs) have been established for Candida spp. with anidulafungin, caspofungin and micafungin when using the Sensititre YeastOne ®: (SYO) broth dilution colorimetric method. In addition, reference caspofungin MICs have so far proven to be unreliable. Candida species wild-type (WT) MIC distributions (microorganisms in a species-drug combination with no detectable phenotypic resistance) were established for 6,007 Candida albicans, 186 C. dubliniensis, 3,188 C. glabrata complex, 119 C. guilliermondii, 493 C. krusei, 205 C. lusitaniae, 3,136 C. parapsilosis complex, and 1,016 C. tropicalis isolates. SYO MIC data gathered from 38 laboratories in Australia, Canada, Europe, Mexico, New Zealand, South Africa, and the United States were pooled to statistically define SYO-ECVs. ECVs of anidulafungin, caspofungin and micafungin encompassing ≥97.5% of the statistically-modeled population were, respectively, 0.12, 0.25, 0.06 μg/ml for C. albicans, 0.12, 0.25, 0.03 μg/mL for C. glabrata complex, 4, 2, 4 μg/ml for C. parapsilosis complex, 0.5, 0.25, 0.06 μg/ml for C. tropicalis, 0.25, 1, 0.25 μg/ml for C. krusei, 0.25, 1, 0.12 μg/ml for C. lusitaniae, 4, 2, 2 μg/ml for C. guilliermondii, and 0.25, 0.25, 0.12 μg/ml for C. dubliniensis. Species-specific SYO-ECVs of anidulafungin, caspofungin and micafungin correctly classified 72 (88.9%), 74 (91.4%), 76 (93.8%), respectively, of 81 Candida isolates with identified fks mutations. SYO-ECVs may aid in detecting non-WT isolates with reduced susceptibility to anidulafungin, micafungin and especially to caspofungin, since testing the susceptibilities of Candida spp. to caspofungin by reference methodologies is not recommended.

Hits: 0